A new method to quantify the effect of co-medication on the efficacy of abiraterone in metastatic castration-resistant prostate cancer patients

Background and Objective: Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) have co-morbidities treated with different drugs. The aim was to quantify the potential effect of co-medications on AA treatment duration (TD) and overall survival (O...

Descripción completa

Detalles Bibliográficos
Autores principales: Fekete, Bertalan, Bársony, Lili, Biró, Krisztina, Gyergyay, Fruzsina, Géczi, Lajos, Patócs, Attila, Budai, Barna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568029/
https://www.ncbi.nlm.nih.gov/pubmed/37841911
http://dx.doi.org/10.3389/fphar.2023.1220457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568029/
https://www.ncbi.nlm.nih.gov/pubmed/37841911
http://dx.doi.org/10.3389/fphar.2023.1220457

Ejemplares similares